ArticleAmerican heart journal plus : cardiology research and practice2025
The design and rationale of the cardiac REHABilitation to improve metabolic health in Hypertrophic CardioMyopathy (REHAB-HCM) Study.
Article in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Shared Decision Making on Methylphenidate in Hypertrophic Cardiomyopathy and ADHD in a Young Athlete.JACC. Case reports · 2026Article
- 2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology.Acta Cardiologica Sinica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study objective: Hypertrophic cardiomyopathy (HCM) is the most common genetic myocardial disorder increasingly characterized by concomitant metabolic syndrome. Cardiac rehabilitation (CR) has been shown to improve metabolic parameters in populations with heart failure and myocardial infarction. However, there is a paucity of data on the impact of CR in the HCM population with metabolic syndrome. We designed the REHAB-HCM study to explore the feasibility, safety, and efficacy of CR in HCM patients with metabolic syndrome. Design: Prospective observation cohort study. Setting: A multi-disciplinary HCM clinic and Multidisciplinary Exercise-based Cardiac Rehabilitation program. Participants: Patients aged 18-80 years old diagnosed with HCM and metabolic syndrome, defined by the American Heart Association and American College of Cardiology guidelines, and the National Cholesterol Education Adult Treatment Panel III (NCEP-ATP III) criteria. Intervention: A structured 3-month CR program with 6 months extended follow-up of physical activity levels. Main outcome measures: Feasibility (e.g., attendance), safety (e.g., major adverse events and exercise-related harms), and efficacy pertaining to long term improvements in physical activity levels, metabolic health, cardiorespiratory fitness, quality of life, and systemic and cellular markers of inflammation. Conclusion: This prospective cohort study will address an important knowledge gap by evaluating the effect of an organized CR program in HCM patients and metabolic syndrome. It is anticipated that exercise and CR will be feasible and beneficial for this complex patient population without significant exercise-related harms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.